Celltrion Applies for Approval of Cosentyx Biosimilar in Canada
Application for CT-P55 Marketing Approval in Canada
Covers All Original Indications
Celltrion has applied for marketing approval of CT-P55, a biosimilar of Cosentyx (ingredient name: secukinumab), an autoimmune disease treatment, in Canada, marking the company's entry into the North American market.
On June 1, Celltrion announced that it had submitted an application to Health Canada for the approval of CT-P55. The application covers all indications for which Cosentyx is approved in Canada, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.
This application is based on the results of a clinical trial conducted in 172 healthy adults. CT-P55 demonstrated pharmacokinetic (PK) equivalence compared to the original drug and also proved similarity in terms of safety and immunogenicity.
Starting with approval in Canada, Celltrion plans to sequentially pursue approval procedures in major markets, including the United States, Europe, and Korea.
CT-P55 is an interleukin (IL)-17A inhibitor and is expected to expand Celltrion's portfolio of autoimmune disease treatments. The company has built a product lineup that spans TNF-α inhibitors and interleukin inhibitors through products such as Remsima, Remsima SC (marketed as Zymfentra in the United States), Yuflyma, Stekimma, and Aptozyma.
The market potential is significant. Last year, the original drug Cosentyx recorded global sales of approximately USD 6.668 billion (about KRW 10 trillion).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Celltrion aims to use Canada, where biosimilar adoption policies are well established, as a bridgehead for entering the North American market. The company plans to expand its current portfolio of 11 biosimilar products to 18 by 2030. In the autoimmune disease field, biosimilars such as Ocrevus (CT-P53) and Taltz (CT-P52) are under development, while in oncology, biosimilars of Keytruda (CT-P51) and Darzalex (CT-P44) are also being developed.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.